{
  "ticker": "SNT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973745",
  "id": "02973745",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250729",
  "time": "0937",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m7w4hpvk67h5.pdf",
  "summary": "- **Clinical Trial Milestone**: First participant dosed in Phase 1a/b trial for SNT-9465 (topical anti-fibrotic drug targeting hypertrophic scars).  \n- **Key Catalyst**: Trial results expected in H1 2026, supporting FDA Investigational New Drug (IND) application.  \n- **Market Opportunity**: Hypertrophic scars represent a ~$3.5B market with no approved pharmacological treatments currently available.  \n\n*No material capital markets or trading-specific information (e.g., capital raising, timetable, or financials) identified.*",
  "usage": {
    "prompt_tokens": 1764,
    "completion_tokens": 117,
    "total_tokens": 1881,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T23:52:32.425801"
}